Literature DB >> 34214170

BOLD asynchrony elucidates tumor burden in IDH-mutated gliomas.

Petros D Petridis1,2, Craig I Horenstein3, Brianna Pereira1, Peter B Wu1, Jorge Samanamud4, Tamara Marie5, Deborah Boyett4, Tejaswi D Sudhakar4, Sameer A Sheth6, Guy M McKhann4, Michael B Sisti4, Jeffrey N Bruce4, Peter Canoll7, Jack Grinband8,9.   

Abstract

BACKGROUND: Gliomas comprise the most common type of primary brain tumor, are highly invasive, and often fatal. IDH-mutated gliomas are particularly challenging to image and there is currently no clinically accepted method for identifying the extent of tumor burden in these neoplasms. This uncertainty poses a challenge to clinicians who must balance the need to treat the tumor while sparing healthy brain from iatrogenic damage. The purpose of this study was to investigate the feasibility of using resting-state blood oxygen level-dependent (BOLD) functional magnetic resonance imaging (fMRI) to detect glioma-related asynchrony in vascular dynamics for distinguishing tumor from healthy brain.
METHODS: Twenty-four stereotactically localized biopsies were obtained during open surgical resection from ten treatment-naïve patients with IDH-mutated gliomas who received standard-of-care preoperative imaging as well as echo-planar resting-state BOLD fMRI. Signal intensity for BOLD asynchrony and standard-of-care imaging was compared to cell counts of total cellularity (H&E), tumor density (IDH1 & Sox2), cellular proliferation (Ki67), and neuronal density (NeuN), for each corresponding sample.
RESULTS: BOLD asynchrony was directly related to total cellularity (H&E, P = 4 × 10-5), tumor density (IDH1, P = 4 × 10-5; Sox2, P = 3 × 10-5), cellular proliferation (Ki67, P = .002), and inversely related to neuronal density (NeuN, P = 1 × 10-4).
CONCLUSIONS: Asynchrony in vascular dynamics, as measured by resting-state BOLD fMRI, correlates with tumor burden and provides a radiographic delineation of tumor boundaries in IDH-mutated gliomas.
© The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  BOLD asynchrony; IDH-mutated glioma; infiltration; resting-state fMRI; tumor burden

Mesh:

Substances:

Year:  2022        PMID: 34214170      PMCID: PMC8730764          DOI: 10.1093/neuonc/noab154

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   13.029


  49 in total

1.  NRG brain tumor specialists consensus guidelines for glioblastoma contouring.

Authors:  Tim J Kruser; Walter R Bosch; Shahed N Badiyan; Joseph A Bovi; Amol J Ghia; Michelle M Kim; Abhishek A Solanki; Sean Sachdev; Christina Tsien; Tony J C Wang; Minesh P Mehta; Kevin P McMullen
Journal:  J Neurooncol       Date:  2019-03-19       Impact factor: 4.130

2.  Glioblastoma therapy in the elderly and the importance of the extent of resection regardless of age.

Authors:  Agi Oszvald; Erdem Güresir; Matthias Setzer; Hartmut Vatter; Christian Senft; Volker Seifert; Kea Franz
Journal:  J Neurosurg       Date:  2011-09-23       Impact factor: 5.115

3.  R132H mutation in IDH1 gene reduces proliferation, cell survival and invasion of human glioma by downregulating Wnt/β-catenin signaling.

Authors:  Daming Cui; Jie Ren; Jinlong Shi; Lijing Feng; Ke Wang; Tao Zeng; Yi Jin; Liang Gao
Journal:  Int J Biochem Cell Biol       Date:  2016-02-06       Impact factor: 5.085

4.  Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas.

Authors:  M Kunz; N Thon; S Eigenbrod; C Hartmann; R Egensperger; J Herms; J Geisler; C la Fougere; J Lutz; J Linn; S Kreth; A von Deimling; J C Tonn; H A Kretzschmar; G Pöpperl; F W Kreth
Journal:  Neuro Oncol       Date:  2011-02-03       Impact factor: 12.300

5.  Sodium Fluorescein Facilitates Guided Sampling of Diagnostic Tumor Tissue in Nonenhancing Gliomas.

Authors:  Stephen G Bowden; Justin A Neira; Brian J A Gill; Timothy H Ung; Zachary K Englander; George Zanazzi; Peter D Chang; Jorge Samanamud; Jack Grinband; Sameer A Sheth; Guy M McKhann; Michael B Sisti; Peter Canoll; Randy S D'Amico; Jeffrey N Bruce
Journal:  Neurosurgery       Date:  2018-05-01       Impact factor: 4.654

Review 6.  Surgical oncology for gliomas: the state of the art.

Authors:  Nader Sanai; Mitchel S Berger
Journal:  Nat Rev Clin Oncol       Date:  2017-11-21       Impact factor: 66.675

7.  Low-grade gliomas: do changes in rCBV measurements at longitudinal perfusion-weighted MR imaging predict malignant transformation?

Authors:  Nasuda Danchaivijitr; Adam D Waldman; Daniel J Tozer; Christopher E Benton; Gisele Brasil Caseiras; Paul S Tofts; Jeremy H Rees; H Rolf Jäger
Journal:  Radiology       Date:  2008-04       Impact factor: 11.105

8.  IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection.

Authors:  Jason Beiko; Dima Suki; Kenneth R Hess; Benjamin D Fox; Vincent Cheung; Matthew Cabral; Nicole Shonka; Mark R Gilbert; Raymond Sawaya; Sujit S Prabhu; Jeffrey Weinberg; Frederick F Lang; Kenneth D Aldape; Erik P Sulman; Ganesh Rao; Ian E McCutcheon; Daniel P Cahill
Journal:  Neuro Oncol       Date:  2013-12-04       Impact factor: 12.300

Review 9.  Imaging biomarkers of brain tumour margin and tumour invasion.

Authors:  S J Price; J H Gillard
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

Review 10.  FSL.

Authors:  Mark Jenkinson; Christian F Beckmann; Timothy E J Behrens; Mark W Woolrich; Stephen M Smith
Journal:  Neuroimage       Date:  2011-09-16       Impact factor: 6.556

View more
  2 in total

1.  RP-Rs-fMRIomics as a Novel Imaging Analysis Strategy to Empower Diagnosis of Brain Gliomas.

Authors:  Xiaoxue Liu; Jianrui Li; Qiang Xu; Qirui Zhang; Xian Zhou; Hao Pan; Nan Wu; Guangming Lu; Zhiqiang Zhang
Journal:  Cancers (Basel)       Date:  2022-06-07       Impact factor: 6.575

2.  BOLD asynchrony: An imaging biomarker of tumor burden in IDH-mutated gliomas.

Authors:  Behroze Adi Vachha; Raymond Y Huang
Journal:  Neuro Oncol       Date:  2022-01-05       Impact factor: 12.300

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.